Point of View: What next for gain-of-function research in Europe?
- European Academies Science Advisory Council, Germany
- German National Academy of Sciences Leopoldina, Germany
Abstract
A working group on gain-of-function research set up by the European Academies Science Advisory Council (EASAC) has emphasised the importance of ensuring that the necessary safeguards and policies are in place
Main text
Infectious diseases continue to be responsible for a substantial proportion of deaths worldwide and there is evidence for a significant increase in the number of outbreaks over the past 30 years. Although some of this increase may be due to improved detection and reporting, animal diseases that can be transmitted to humans are among the major causes of human infection (Smith et al., 2014).
Influenza outbreaks are a particular concern: in the UK, for example, the potential impact of an influenza pandemic has been identified as the highest priority in the UK Government Risk Register for 2015. Our current inability to predict which specific virus subtypes will trigger the next influenza pandemic highlights the vital importance of addressing gaps in the knowledge base. Research on a wide range of topics—including the study of virus transmission, host range, drug resistance, infectivity, immunity and virulence—is urgently needed to fill these gaps. In this article we focus on the issues raised by proposals to use ‘gain-of-function’ experiments to fill some of these gaps. Such experiments have a long history of providing useful information in virology.
Gain-of-function experiments involve modifying a virus and analysing the link between modified genotype and phenotype. However, proposals to modify the H5N1 variant of the influenza virus in order to affect its transmission potential, and thereby understand the factors that determine the ability of an animal virus to spread to humans (and between humans) by the aerosol route, were controversial (Russell et al., 2014; Schultz-Cherry et al., 2014; Palu, 2014; Wain-Hobson, 2014), and there is still a de facto moratorium on such research in the US.
Self-regulation is a necessary first step for gain-of-function research, but this does not mean that each researcher is free to decide for themselves what procedures to follow.
Experiments are of concern if they have the potential to cause serious disease, and these concerns encompass biosafety (relating to the accidental release of a pathogen from containment), biosecurity (relating to intentional misuse; see NRC, 2004), and bioethics (the principles and their place in research review procedures). Although potentially dangerous research studies are already subject to stringent regulations in many countries, recent controversies prompted the European Academies Science Advisory Council (EASAC) to set up a working group to examine the issues raised by gain-of-function research and to make recommendations for the management of such research and its outputs in the EU. This working group contained the present authors and other scientists with a wide range of relevant experience. Here we discuss some of the recommendations made by the working group (see EASAC, 2015 for the full report).
Scientific responsibility and benefit-risk assessment
Self-regulation is a necessary first step for gain-of-function research, but this does not mean that each researcher is free to decide for themselves what procedures to follow. Everyone involved must conform to existing regulations, codes of conduct and established methods for biorisk management (see EASAC, 2015 for a list of existing regulations in Europe, and details of work by the World Health Organisation and the OECD in this area).
Moreover, proposals for gain-of-function studies—particularly those that intend to alter virus transmission, host range, drug resistance, infectivity, immunity and virulence—have to be justified by their authors to a wide range of bodies (the institutions where the work will be carried out, the agencies that will fund the work, the relevant ethics committees, and the relevant national authorities), as well as their peers, on a case-by-case basis. This process must involve a thorough analysis of the risks and benefits of the research being proposed. Researchers also need to demonstrate that the information they need can only be obtained from gain-of-function experiments.
A clear theme in both Europe and the US is the need for the scientific community to engage more broadly with the public, explaining the reasons for doing gain-of-function research.
There are many uncertainties in the data used to evaluate benefit and risk, and this can lead to controversy. It should also be acknowledged that potential benefits of research are sometimes overstated by scientists: however, it is also true that the benefits of research might only become clear much later. Views vary on whether benefit should be quantified in terms of future public health impact or described in terms of the generation of knowledge, and on the extent to which benefits may be lost if research is not allowed. There have been concerns that research that could help to streamline the production of vaccines might suffer if gain-of-function experiments are banned (Cohen, 2015; Ping et al., 2015). Because of the multiple challenges involved in assessing risk and benefit, the EASAC report concludes that any benefit-risk analysis cannot be regarded as a ‘once and for all’ calculation, and that all the relevant parties need to understand and communicate the issues on an on-going basis.
The EASAC report also recommends that there is no need for a new advisory body at the EU level. Rather, all EU Member States should have a clear national advisory mechanism on procedures for assessing and managing biosafety and biosecurity risks. In the UK, for example, the Health and Safety Executive has statutory powers, but other EU Member States have different mechanisms and not all have statutory powers. There is need to harmonise the implementation of good practice in these respects. All countries should also adopt a ‘layered’ approach with researchers, research institutions, research funders and national authorities all being responsible for the regulation of gain-of-function research. Such a layered approach at the country level will spread good practice, increase accountability, and help to improve public trust in research.
Researchers and institutions also have to recognise their responsibility to make decisions about publishing sensitive information and, together with funders, ethics committees and others, need to consider these issues throughout the research process, starting when the research is first proposed, rather than delaying the decision until a manuscript is ready for submission to a journal. The oversight within the scientific community must involve journals and professional societies, as well as researchers, their funders and institutions (and national advisory bodies in complex cases). Journal editors in the US recently came to a similar conclusion (Casadevall et al., 2015). Regarding the question of what to do when European researchers submit a manuscript to a journal that is not based in Europe, EASAC advises that the use of the EU’s export control regime is an inappropriate and ineffective vehicle to block such submissions.
Many of EASAC’s recommendations have been welcomed by the European Commission, who will now consider how to incorporate EASAC advice into guidance for Horizon 2020 research grant applicants and evaluators.
The EASAC report resonates with the themes that are emerging from discussions in the US involving the National Academies, the National Science Advisory Board for Biosecurity (NSABB) and the National Institutes of Health. A National Academies workshop in December 2014 observed that the challenges involved in regulating gain-of-function research were international, that attention should be focussed on those experiments of greatest concern, that researchers and their institutions must accept responsibility, and that analysing the risks and benefits is not straightforward. Since then, a quantitative risk-benefit analysis has been initiated (Casagrande et al., 2015), and the NSABB has set up a working group to look into the issues surrounding gain-of-function research (Kanabrocki, 2015). In its interim report the NASBB working group noted that the US already has a robust policy framework for the regulation of research, and any future policies should build on this framework.
Challenges for wider engagement
A clear theme in both Europe and the US is the need for the scientific community to engage more broadly with the public, explaining the reasons for doing gain-of-function research, discussing the potential risks and benefits of this research, and explaining the biorisk management practices adopted. Engagement with public interests can be considered at three levels. First, on the global scale, the scientific community has to ensure that the public health benefits that arise from innovation based on gain-of-function research are made available to everyone. Second, on the national level, scientists need to convince the public that taxpayer funds are being spent wisely. Third, on a local level, scientists must engage with those who live near research facilities to reassure them about safety.
Another clear theme is the need for the regulatory authorities, funding bodies and professional societies in different countries to work together to share expertise in the regulation of gain-of-function research and in risk-benefit analysis. Academies of science have a clear role to play at the national level, and international networks of academies can bring scientists from different countries together to study and make recommendations on specific issues: the working group on biosecurity set up by the InterAcademy Partnership is an example of this.
Influenza pandemics are currently unpredictable. However, we still need to be ready for the next pandemic, and that includes being in a position to perform gain-of-function research if that is the only way to obtain the information needed to deal with the pandemic. And, as should be clear from above, this means that many different stakeholders—scientists, institutions, funding agencies, ethics committees, national regulatory authorities, scientific societies and journals—need to work together to ensure that we are prepared.
References
-
Development of high-yield influenza a virus vaccine virusesNature Communications 8148.https://doi.org/10.1038/ncomms9148
-
Global rise in human infectious disease outbreaksJournal of the Royal Society Interface 11:20140950.https://doi.org/10.1098/rsif.2014.0950
-
The irrationality of GOF avian influenza virus researchFrontiers in Public Health 2:.https://doi.org/10.3389/fpubh.2014.00077
Article and author information
Author details
Acknowledgements
We thank all the members of the EASAC Working Group: Goran Hermeren (Sweden), Ursula Jenal (Switzerland), Hans Klenk (Germany), Andre Knottnerus (The Netherlands), Maria Masucci (Sweden), John McCauley (UK), Thomas Mettenleiter (Germany), Giorgio Palu (Italy), Gyorgy Posfai (Hungary), Bert Rima (Ireland), John Skehel (UK), and Simon Wain-Hobson (France).
Publication history
- Received:
- Accepted:
- Version of Record published:
Copyright
© 2015, Fears et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,619
- views
-
- 166
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Point of View: What next for gain-of-function research in Europe?
eLife 4:e13035.
https://doi.org/10.7554/eLife.13035
Further reading
-
- Genetics and Genomics
- Microbiology and Infectious Disease
The sustained success of Mycobacterium tuberculosis as a pathogen arises from its ability to persist within macrophages for extended periods and its limited responsiveness to antibiotics. Furthermore, the high incidence of resistance to the few available antituberculosis drugs is a significant concern, especially since the driving forces of the emergence of drug resistance are not clear. Drug-resistant strains of Mycobacterium tuberculosis can emerge through de novo mutations, however, mycobacterial mutation rates are low. To unravel the effects of antibiotic pressure on genome stability, we determined the genetic variability, phenotypic tolerance, DNA repair system activation, and dNTP pool upon treatment with current antibiotics using Mycobacterium smegmatis. Whole-genome sequencing revealed no significant increase in mutation rates after prolonged exposure to first-line antibiotics. However, the phenotypic fluctuation assay indicated rapid adaptation to antibiotics mediated by non-genetic factors. The upregulation of DNA repair genes, measured using qPCR, suggests that genomic integrity may be maintained through the activation of specific DNA repair pathways. Our results, indicating that antibiotic exposure does not result in de novo adaptive mutagenesis under laboratory conditions, do not lend support to the model suggesting antibiotic resistance development through drug pressure-induced microevolution.
-
- Microbiology and Infectious Disease
Bacillus velezensis is a species of Bacillus that has been widely investigated because of its broad-spectrum antimicrobial activity. However, most studies on B. velezensis have focused on the biocontrol of plant diseases, with few reports on antagonizing Salmonella Typhimurium infections. In this investigation, it was discovered that B. velezensis HBXN2020, which was isolated from healthy black pigs, possessed strong anti-stress and broad-spectrum antibacterial activity. Importantly, B. velezensis HBXN2020 did not cause any adverse side effects in mice when administered at various doses (1×107, 1×108, and 1×109 CFU) for 14 days. Supplementing B. velezensis HBXN2020 spores, either as a curative or preventive measure, dramatically reduced the levels of S. Typhimurium ATCC14028 in the mice’s feces, ileum, cecum, and colon, as well as the disease activity index (DAI), in a model of infection caused by this pathogen in mice. Additionally, supplementing B. velezensis HBXN2020 spores significantly regulated cytokine levels (Tnfa, Il1b, Il6, and Il10) and maintained the expression of tight junction proteins and mucin protein. Most importantly, adding B. velezensis HBXN2020 spores to the colonic microbiota improved its stability and increased the amount of beneficial bacteria (Lactobacillus and Akkermansia). All together, B. velezensis HBXN2020 can improve intestinal microbiota stability and barrier integrity and reduce inflammation to help treat infection by S. Typhimurium.
